Arrowhead Pharma (ARWR) PT Raised to $123 at B.Riley

July 30, 2026 8:47 AM

B.Riley analyst Chad L. Mabry raised the price target on Arrowhead Pharma (NASDAQ: ARWR) to $123.00 (from $101.00) while maintaining a Buy rating.

No results found